Search

Your search keyword '"Jaume Folch"' showing total 135 results

Search Constraints

Start Over You searched for: Author "Jaume Folch" Remove constraint Author: "Jaume Folch"
135 results on '"Jaume Folch"'

Search Results

1. Exploring small non-coding RNAs as blood-based biomarkers to predict Alzheimer’s disease

2. A novel rhein-huprine hybrid ameliorates disease-modifying properties in preclinical mice model of Alzheimer’s disease exacerbated with high fat diet

3. JNK1 and JNK3: divergent functions in hippocampal metabolic-cognitive function

4. Dexibuprofen ameliorates peripheral and central risk factors associated with Alzheimer’s disease in metabolically stressed APPswe/PS1dE9 mice

5. Peroxisomal Proliferator-Activated Receptor β/δ Deficiency Induces Cognitive Alterations

6. Impact of New Drugs for Therapeutic Intervention in Alzheimer’s Disease

7. Dexibuprofen prevents neurodegeneration and cognitive decline in APPswe/PS1dE9 through multiple signaling pathways

8. Benzodiazepines and Related Drugs as a Risk Factor in Alzheimer's Disease Dementia

9. The Involvement of Peripheral and Brain Insulin Resistance in Late Onset Alzheimer’s Dementia

10. Involvement of JNK1 in Neuronal Polarization During Brain Development

11. Current Research Therapeutic Strategies for Alzheimer’s Disease Treatment

12. The Implication of the Brain Insulin Receptor in Late Onset Alzheimer’s Disease Dementia

13. Lipoprotein Particle Profiles Associated with Telomere Length and Telomerase Complex Components

14. Protein tyrosine phosphatase 1B (PTP1B) as a potential therapeutic target for neurological disorders

15. Dexibuprofen ameliorates peripheral and central risk factors associated with Alzheimer’s disease in metabolically stressed APPswe/PS1dE9 mice

16. Pharmacological Strategies to Improve Dendritic Spines in Alzheimer’s Disease

18. Impact of New Drugs for Therapeutic Intervention in Alzheimer's Disease

19. GSPE pre-treatment protects against long-term cafeteria diet-induced mitochondrial and inflammatory affectations in the hippocampus of rats

20. Effects of Nutrition on Cognitive Function in Adults with or without Cognitive Impairment: A Systematic Review of Randomized Controlled Clinical Trials

21. Peroxisomal Proliferator-Activated Receptor β/δ Deficiency Induces Cognitive Alterations

22. c-Jun N-terminal Kinase 1 ablation protects against metabolic-induced hippocampal cognitive impairments

23. Role of brain c‐Jun N‐terminal kinase 2 in the control of the insulin receptor and its relationship with cognitive performance in a high‐fat diet pre‐clinical model

24. Microplastics levels, size, morphology and composition in marine water, sediments and sand beaches. Case study of Tarragona coast (western Mediterranean)

25. Epigallocatechin-3-gallate PEGylated poly(lactic-co-glycolic) acid nanoparticles mitigate striatal pathology and motor deficits in 3-nitropropionic acid intoxicated mice

26. The preclinical discovery and development of opicapone for the treatment of Parkinson's disease

27. JNK Isoforms Are Involved in the Control of Adult Hippocampal Neurogenesis in Mice, Both in Physiological Conditions and in an Experimental Model of Temporal Lobe Epilepsy

28. JNK1 inhibition by Licochalcone A leads to neuronal protection against excitotoxic insults derived of kainic acid

29. Una revisión de los avances en la terapéutica de la enfermedad de Alzheimer: estrategia frente a la proteína β-amiloide

30. Early Preclinical Changes in Hippocampal CREB-Binding Protein Expression in a Mouse Model of Familial Alzheimer’s Disease

31. Long-term exposition to a high fat diet favors the appearance of β-amyloid depositions in the brain of C57BL/6J mice. A potential model of sporadic Alzheimer’s disease

32. Correction to: Peripheral and Central Effects of Memantine in a Mixed Preclinical Mice Model of Obesity and Familial Alzheimer’s Disease

33. Involvement of JNK1 in neuronal polarization during brain development

34. Role of c-Jun N-Terminal Kinases (JNKs) in Epilepsy and Metabolic Cognitive Impairment

35. Epigallocatechin-3-Gallate (EGCG) Improves Cognitive Deficits Aggravated by an Obesogenic Diet Through Modulation of Unfolded Protein Response in APPswe/PS1dE9 Mice

36. Effects of MDMA on neuroplasticity, amyloid burden and phospho-tau expression in APPswe/PS1dE9 mice

37. A metabolic perspective of late onset Alzheimer's disease

38. Triple GLP-1/GIP/glucagon receptor agonists, a potential novel treatment strategy in Alzheimer's disease

39. The Ethyl Acetate Extract of Leaves of Ugni molinae Turcz. Improves Neuropathological Hallmarks of Alzheimer's Disease in Female APPswe/PS1dE9 Mice Fed with a High Fat Diet

40. Dual-drug loaded nanoparticles of Epigallocatechin-3-gallate (EGCG)/Ascorbic acid enhance therapeutic efficacy of EGCG in a APPswe/PS1dE9 Alzheimer's disease mice model

41. Masitinib for the treatment of mild to moderate Alzheimer’s disease

42. Hypercholesterolemia and neurodegeneration. Comparison of hippocampal phenotypes in LDLr knockout and APPswe/PS1dE9 mice

43. Memantine for the treatment of dementia. A review on its current and future applications

44. Experimental Models for Aging and their Potential for Novel Drug Discovery

45. The Implication of the Brain Insulin Receptor in Late Onset Alzheimer's Disease Dementia

46. Epigallocatechin-3-gallate loaded PEGylated-PLGA nanoparticles: A new anti-seizure strategy for temporal lobe epilepsy

47. Neuroprotective Effects of the Absence of JNK1 or JNK3 Isoforms on Kainic Acid-Induced Temporal Lobe Epilepsy-Like Symptoms

48. Review of the advances in treatment for Alzheimer disease: strategies for combating β-amyloid protein

49. Adipokine pathways are altered in hippocampus of an experimental mouse model of Alzheimer’s disease

50. Early alterations in energy metabolism in the hippocampus of APPswe/PS1dE9 mouse model of Alzheimer's disease

Catalog

Books, media, physical & digital resources